Adagrasib is a targeted anticancer medication developed to treat tumors with a specific genetic mutation known as KRAS G12C, most commonly found in non-small cell lung cancer. It was created by Mirati Therapeutics as part of a new class of precision oncology drugs aimed at directly inhibiting KRAS, a protein long considered “undruggable” in cancer research. Early laboratory discoveries in the 2010s paved the way for adagrasib’s development, followed by clinical trials demonstrating its effectiveness in shrinking tumors and improving outcomes in patients with advanced cancers. Its progress marked a major milestone in cancer therapy, leading to accelerated approval by the U.S. Food and Drug Administration in 2022 for certain patients with previously treated KRAS G12C-mutated non-small cell lung cancer, highlighting a significant breakthrough in personalized medicine.
